News

Filter

Current filters:

FranceNicOx

NicOx's acquisitions pay off as sales rocket to 4 million euros in third quarter

NicOx's acquisitions pay off as sales rocket to 4 million euros in third quarter

30-10-2014

French pharma company NicOx has achieved sales of 4 million euros ($5 million) in the third quarter of…

FinancialFranceNicOxOphthalmicsPharmaceutical

NicOx and Valeant's glaucoma candidate Vesneo meets Ph III endpoint

NicOx and Valeant's glaucoma candidate Vesneo meets Ph III endpoint

25-09-2014

Canada’s Valeant Pharmaceuticals International and France’s NicOx have reported positive top-line…

Bausch & LombCanadaFinancialFranceNicOxOphthalmicsPharmaceuticalResearchValeant Pharmaceuticals InternationalVesneo

NicOx appoints financial partner to assess Duchenne Muscular Dystrophy treatment

14-02-2014

French biotechnology firm NicOx (Euronext Paris: COX) has granted an undisclosed financial partner an…

BiotechnologyFranceGeneticsLicensingnaproxcinodNicOx

Nicox granted exclusive promotion and marketing rights for AMD test in North America

17-01-2014

French biotech firm NicOx SA (NYSE Euronext Paris: COX) and USA-based Sequenom (Nasdaq: SQNM) have entered…

BiotechnologyFranceLicensingNicOxOphthalmicsSequenomUSA

NicOx highlights progress in bid to focus on ophthalmology

07-01-2014

French biotech firm NicOx SA (NYSE Euronext Paris: COX) says it has made significant progress in 2013…

BiotechnologyFinancialFranceNicOxOphthalmics

COMPANY SPOTLIGHT

Menarini

Back to top